Eli Lilly's Tirzepatide Study Targets Adolescents with Obesity and Comorbidities
Eli Lilly is conducting a study to evaluate tirzepatide's effects on weight and cardiovascular risk in adolescents with obesity.
Therapeutic Area
Therapeutic area intelligence for GLP-1 Agonist with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.